Wyeth Holdings Corporation

Serono Genetics Institute S.a.

Wyeth

American Cyanamid Company

Genset S.a.

Merck Serono Biodevelopment

Serono Genetica Institute S.a.

Robert J Zagursky

Leah Diane Fletcher

Benjamin J Metcalf

Gary Warren Zlotnick

John Erwin Farley

Liesel A Bernfield

Joel A Peek

Susan K Hoiseth

Banumathi Sankaran

Rémy Griffais

Bruce Arthur Green

Amy Wadhams Masi

Joseph Lawrence Wooters

Deb Narayan Chakravarti

David Parrish Russell

Peggy Ooi

The present invention relates toORF2086 proteins, crossreactive immunogenic proteins which can be isolated from nesserial strains or prepared recombinantly, including immunogenic portions thereof, biological equivalents thereof, antibodies that immunospecifically bind to the foregoing and nucleic acid sequences encoding each of the foregoing, as well as the use of same in immunogenic compositions that are effective against infection byserogroup B.

Immunogenic compositions for the prevention and treatment of meningococcal disease

The present invention relates to newly identified open reading frames comprised within the genomic nucleotide sequence of, wherein the open reading frames encode polypeptides that are surface localized on. Thus, the invention relates toopen reading frames that encode polypeptide antigens, polypeptides, preferably antigenic polypeptides, encoded by theopen reading frames, vectors comprising open reading frame sequences and cells or animals transformed with these vectors. The invention relates also to methods of detecting these nucleic acids or polypeptides and kits for diagnosinginfection. The invention finally relates to pharmaceutical compositions, in particular immunogenic compositions, for the prevention and/or treatment of bacterial infection, in particular infections with. In particular embodiments, the immunogenic compositions are used for the treatment or prevention of systemic diseases which are induced or exacerbated by. In other embodiments, the immunogenic compositions are used for the treatment or prevention of non-systemic diseases, particularly of the otitis media, which are induced or exacerbated by

[object Object]

The subject of the invention is the genomic sequence and the nucleotide sequences encoding polypeptides of, such as cellular envelope polypeptides, which are secreted or specific, or which are involved in metabolism, in the replication process or in virulence, polypeptides encoded by such sequences, as well as vectors including the said sequences and cells or animals transformed with these vectors. The invention also relates to transcriptional gene products of thegenome, such as, for example, antisense and ribozyme molecules, which can be used to control growth of the microorganism. The invention also relates to methods of detecting these nucleic acids or polypeptides and kits for diagnosinginfection. The invention also relates to a method of selecting compounds capable of modulating bacterial infection and a method for the biosynthesis or biodegradation of molecules of interest using the said nucleotide sequences or the said polypeptides. The invention finally comprises, pharmaceutical, in particular vaccine, compositions for the prevention and/or treatment of bacterial, in particular, infections.

Growing community of inventors

Victor, NY, United States of America

Robert J Zagursky